Clinical Trials Directory

Trials / Completed

CompletedNCT04020666

Effects of Urinary Kallidinogenase in Acute Ischemic Stroke Patients With Abnormal Glucose Metabolism

Effects of Urinary Kallidinogenase on NIHSS Score, mRS Score, and Fasting Glucose Levels in Acute Ischemic Stroke Patients With Abnormal Glucose Metabolism: a Prospective Cohort Study

Status
Completed
Phase
Study type
Observational
Enrollment
113 (actual)
Sponsor
The Second Hospital of Hebei Medical University · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Urinary kallidinogenase may assist recovery acute ischemic stroke. This study evaluated the impact of urinary kallidinogenase on NIHSS score, modified Rankin scale (mRS) score and fasting glucose levels in patients with AIS combined with diabetes mellitus and impaired fasting glucose.

Detailed description

Patients with AIS and abnormal glucose metabolism were enrolled in this prospective cohort study and divided into two groups. The HUK group were treated with urinary kallidinogenase and standard treatment, the control group received standard treatment. NIHSS scores, mRS scores and fasting blood glucose were evaluated and compared.

Conditions

Interventions

TypeNameDescription
DRUGUrinary Kallidinogenase

Timeline

Start date
2016-12-01
Primary completion
2017-10-01
Completion
2017-10-01
First posted
2019-07-16
Last updated
2019-07-16

Source: ClinicalTrials.gov record NCT04020666. Inclusion in this directory is not an endorsement.